O	0	8	Sentinel
O	9	13	node
O	14	20	biopsy
O	21	23	in
O	24	30	breast
O	31	37	cancer
O	37	38	:
O	39	49	validation
O	50	55	study
O	56	59	and
O	60	70	comparison
O	71	73	of
B-intervention	74	78	blue
I-intervention	79	82	dye
I-intervention	83	88	alone
O	89	93	with
B-control	94	100	triple
I-control	101	109	modality
I-control	110	122	localization
O	122	123	.

O	124	132	Sentinel
O	133	137	node
O	138	144	biopsy
O	145	146	(
O	146	149	SNB
O	149	150	)
O	151	154	for
O	155	161	breast
O	162	168	cancer
O	169	177	patients
O	178	180	is
O	181	182	a
O	183	186	new
O	187	196	technique
O	197	201	with
O	202	205	the
O	206	215	potential
O	216	218	to
O	219	226	provide
O	227	229	an
O	230	238	accurate
O	239	246	staging
O	247	249	of
O	250	253	the
O	254	262	axillary
O	263	268	nodal
O	269	275	status
O	276	281	while
O	282	290	avoiding
O	291	294	the
O	295	304	morbidity
O	305	307	of
O	308	310	an
O	311	319	axillary
O	320	330	dissection
O	330	331	.

O	332	335	The
O	336	345	objective
O	346	348	of
O	349	352	the
O	353	360	present
O	361	366	study
O	367	369	is
O	370	372	to
O	373	381	validate
O	382	385	the
O	386	389	use
O	390	392	of
O	393	401	sentinel
O	402	406	node
O	407	413	biopsy
O	414	416	in
O	417	418	a
B-location	419	422	New
I-location	423	430	Zealand
O	431	439	hospital
O	440	443	and
O	444	446	to
O	447	454	compare
O	455	458	the
O	459	466	ability
O	467	469	of
O	470	476	patent
O	477	481	blue
O	482	485	dye
O	486	487	(
O	487	489	PB
O	489	490	)
O	491	496	alone
O	497	501	with
O	502	508	triple
O	509	517	modality
O	518	519	(
O	519	521	TM
O	521	522	)
O	523	524	(
O	524	536	preoperative
O	537	555	lymphoscintigraphy
O	555	556	,
O	557	571	intraoperative
O	572	577	gamma
O	578	583	probe
O	584	587	and
O	588	602	intraoperative
O	603	607	blue
O	608	611	dye
O	611	612	)
O	613	615	to
O	616	624	identify
O	625	628	the
O	629	637	sentinel
O	638	642	node
O	642	643	.

O	644	645	A
O	646	651	total
O	652	654	of
B-total-participants	655	658	104
B-eligibility	659	667	patients
I-eligibility	668	671	who
I-eligibility	672	675	had
I-eligibility	676	677	a
I-eligibility	678	686	palpable
I-eligibility	687	693	breast
I-eligibility	694	698	lump
I-eligibility	699	703	that
I-eligibility	704	707	was
I-eligibility	708	717	confirmed
I-eligibility	718	720	to
I-eligibility	721	723	be
I-eligibility	724	733	malignant
I-eligibility	734	736	by
I-eligibility	737	746	radiology
I-eligibility	747	750	and
I-eligibility	751	759	cytology
I-eligibility	760	763	and
I-eligibility	764	765	a
I-eligibility	766	774	clinical
I-eligibility	775	784	diagnosis
I-eligibility	785	787	of
I-eligibility	788	793	stage
I-eligibility	794	795	I
I-eligibility	796	798	or
I-eligibility	799	804	stage
I-eligibility	805	807	II
I-eligibility	808	814	breast
I-eligibility	815	821	cancer
O	821	822	,
O	823	827	were
O	828	836	enrolled
O	837	840	for
O	841	844	SNB
O	845	848	and
O	849	857	randomly
O	858	866	assigned
O	867	869	to
O	870	876	triple
O	877	885	modality
O	886	888	or
O	889	893	blue
O	894	897	dye
O	898	903	alone
O	904	907	for
O	908	911	the
O	912	924	localization
O	925	927	of
O	928	931	the
O	932	940	sentinel
O	941	945	node
O	945	946	.

O	947	955	Axillary
O	956	966	dissection
O	967	970	was
O	971	980	performed
O	981	986	after
O	987	990	the
O	991	999	sentinel
O	1000	1004	node
O	1004	1005	(
O	1005	1006	s
O	1006	1007	)
O	1008	1011	had
O	1012	1016	been
O	1017	1024	removed
O	1024	1025	.

O	1026	1031	There
O	1032	1036	were
B-intervention-participants	1037	1039	63
O	1040	1048	patients
O	1049	1051	in
O	1052	1055	the
O	1056	1058	PB
O	1059	1064	group
O	1065	1068	and
B-control-participants	1069	1071	41
O	1072	1080	patients
O	1081	1083	in
O	1084	1087	the
O	1088	1090	TM
O	1091	1096	group
O	1096	1097	.

O	1098	1102	Both
O	1103	1109	groups
O	1110	1113	are
O	1114	1124	comparable
O	1124	1125	,
O	1126	1130	with
O	1131	1132	a
O	1133	1140	similar
O	1141	1145	mean
O	1146	1149	age
O	1150	1153	and
O	1154	1161	primary
O	1162	1168	tumour
O	1169	1173	size
O	1173	1174	.

O	1175	1176	A
B-outcome	1177	1185	sentinel
I-outcome	1186	1190	node
O	1191	1194	was
O	1195	1205	identified
O	1206	1208	in
B-iv-bin-abs	1209	1211	57
O	1212	1213	(
B-iv-bin-percent	1213	1215	90
I-iv-bin-percent	1215	1216	%
O	1216	1217	)
O	1218	1220	of
O	1221	1224	the
O	1225	1227	PB
O	1228	1233	group
O	1234	1242	patients
O	1243	1246	and
B-cv-bin-abs	1247	1249	40
O	1250	1251	(
B-cv-bin-percent	1251	1253	98
I-cv-bin-percent	1253	1254	%
O	1254	1255	)
O	1256	1258	of
O	1259	1262	the
O	1263	1265	TM
O	1266	1271	group
O	1272	1280	patients
O	1280	1281	.

O	1282	1284	Of
O	1285	1290	these
B-iv-bin-abs	1291	1293	23
O	1294	1295	(
B-iv-bin-percent	1295	1297	37
I-iv-bin-percent	1297	1298	%
O	1298	1299	)
O	1300	1302	of
O	1303	1306	the
O	1307	1309	PB
O	1310	1315	group
O	1316	1319	and
B-cv-bin-abs	1320	1322	23
O	1323	1324	(
B-cv-bin-percent	1324	1326	56
I-cv-bin-percent	1326	1327	%
O	1327	1328	)
O	1329	1331	in
O	1332	1335	the
O	1336	1338	TM
O	1339	1344	group
O	1345	1348	had
B-outcome	1349	1357	axillary
I-outcome	1358	1363	nodes
I-outcome	1364	1372	positive
I-outcome	1373	1376	for
I-outcome	1377	1387	malignancy
O	1387	1388	.

O	1389	1394	There
O	1395	1398	was
B-iv-bin-abs	1399	1402	one
B-outcome	1403	1408	false
I-outcome	1409	1417	negative
I-outcome	1418	1421	SNB
O	1422	1424	in
O	1425	1428	the
O	1429	1431	PB
O	1432	1437	group
O	1438	1441	and
B-cv-bin-abs	1442	1445	two
O	1446	1451	false
O	1452	1460	negative
O	1461	1468	results
O	1469	1471	in
O	1472	1475	the
O	1476	1478	TM
O	1479	1484	group
O	1484	1485	.

O	1486	1495	Therefore
O	1495	1496	,
O	1497	1500	the
O	1501	1503	PB
O	1504	1509	group
O	1510	1513	had
O	1514	1516	an
B-outcome	1517	1525	accuracy
O	1526	1528	of
B-iv-bin-percent	1529	1531	98
I-iv-bin-percent	1531	1532	%
O	1533	1536	and
O	1537	1538	a
B-outcome	1539	1550	sensitivity
O	1551	1553	of
B-cv-bin-percent	1554	1556	96
I-cv-bin-percent	1556	1557	%
O	1558	1566	compared
O	1567	1569	to
O	1570	1572	an
B-outcome	1573	1581	accuracy
O	1582	1584	of
B-cv-bin-percent	1585	1587	95
I-cv-bin-percent	1587	1588	%
O	1589	1592	and
O	1593	1594	a
B-outcome	1595	1606	sensitivity
O	1607	1609	of
B-cv-bin-percent	1610	1612	91
I-cv-bin-percent	1612	1613	%
O	1614	1617	for
O	1618	1621	the
O	1622	1624	TM
O	1625	1630	group
O	1630	1631	.

O	1632	1635	The
O	1636	1643	results
O	1644	1646	of
O	1647	1650	the
O	1651	1658	present
O	1659	1664	study
O	1665	1673	validate
O	1674	1677	the
O	1678	1681	use
O	1682	1684	of
O	1685	1688	SNB
O	1689	1691	in
O	1692	1700	suitable
O	1701	1707	breast
O	1708	1714	cancer
O	1715	1723	patients
O	1723	1724	.

O	1725	1739	Identification
O	1740	1743	and
O	1744	1747	the
O	1748	1756	accuracy
O	1757	1759	of
O	1760	1763	the
O	1764	1772	sentinel
O	1773	1777	node
O	1778	1790	localization
O	1791	1795	were
O	1796	1803	similar
O	1804	1811	between
O	1812	1815	the
O	1816	1819	two
O	1820	1826	groups
O	1826	1827	.

O	1828	1837	Therefore
O	1837	1838	,
O	1839	1841	in
O	1842	1850	hospital
O	1851	1858	centres
O	1859	1866	without
O	1867	1875	adequate
O	1876	1882	access
O	1883	1885	to
O	1886	1887	a
O	1888	1895	nuclear
O	1896	1903	medical
O	1904	1912	facility
O	1912	1913	,
O	1914	1916	it
O	1917	1922	would
O	1923	1925	be
O	1926	1934	feasible
O	1935	1937	to
O	1938	1945	conduct
O	1946	1949	SNB
O	1950	1955	using
O	1956	1960	blue
O	1961	1964	dye
O	1965	1970	alone
O	1970	1971	.
